1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 9,350 | 9,550 | 13:04 | |
| 9,400 | 9,550 | 21.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Fortrea Holdings Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11. | Truist Securities raises Fortrea stock price target to $12 from $7 on Q3 results | 1 | Investing.com | ||
| FORTREA Aktie jetzt für 0€ handeln | |||||
| 05.11. | Fortrea Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Fortrea Q3 2025 slides: Strategic initiatives drive stock surge despite earnings miss | 1 | Investing.com | ||
| 05.11. | Fortrea Holdings Inc. Q3 Earnings Summary | 1 | RTTNews | ||
| 05.11. | Fortrea Holdings reports mixed Q3 results; updates FY25 outlook | 2 | Seeking Alpha | ||
| 05.11. | Fortrea Holdings Inc: Fortrea Reports Third Quarter 2025 Results | 100 | GlobeNewswire (Europe) | For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income... ► Artikel lesen | |
| 05.11. | Fortrea Holdings Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.10. | Fortrea launches $75.7 million debt tender offer for senior notes | 1 | Investing.com | ||
| 20.10. | Fortrea Holdings Inc: Fortrea Announces Tender Offer for up to $75,744,000 Aggregate Purchase Price of Outstanding Debt | 2 | GlobeNewswire (USA) | ||
| 02.10. | Where Fortrea Holdings Stands With Analysts | 9 | Benzinga.com | ||
| 22.09. | Fortrea names William Sharbaugh to board of directors | 2 | Investing.com | ||
| 22.09. | Fortrea beruft William Sharbaugh in den Verwaltungsrat | 1 | Investing.com Deutsch | ||
| 22.09. | Fortrea Holdings Inc. - 8-K, Current Report | 12 | SEC Filings | ||
| 22.09. | Fortrea Holdings Inc: Fortrea Appoints William Sharbaugh to Board of Directors | 1 | GlobeNewswire (USA) | ||
| 12.09. | Fortrea Holdings Inc: Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | 142 | GlobeNewswire (Europe) | DURHAM, N.C., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization, today announced the granting of an inducement award of restricted... ► Artikel lesen | |
| 05.09. | Hedge Fund and Insider Trading News: Bill Ackman, John Paulson, Warren Buffett, Third Point, Starboard Value, Fortrea Holdings Inc (FTRE), Microsoft Corp (MSFT), and More | 31 | Insider Monkey | ||
| 03.09. | Demystifying Fortrea Holdings: Insights From 6 Analyst Reviews | 5 | Benzinga.com | ||
| 01.09. | Fortrea Holdings Inc. - S-8, Securities to be offered to employees in employee benefit plans | 12 | SEC Filings | ||
| 27.08. | Fortrea Holdings Inc. - 8-K, Current Report | 2 | SEC Filings |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 45,700 | -1,08 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AMGEN | 297,10 | +1,38 % | Dividendenbekanntmachungen (21.11.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCO BRANDS CORPORATION US00081T1088 0,075 USD 0,065 EUR ALLISON TRANSMISSION HOLDINGS INC US01973R1014 0,27 USD 0,2341 EUR ALPHAMIN... ► Artikel lesen | |
| NOVAVAX | 5,629 | +0,27 % | Novavax rises after a seven-day slide | ||
| STRYKER | 321,90 | +0,63 % | P/E Ratio Insights for Stryker | ||
| ILLUMINA | 106,66 | -0,80 % | Pacific Biosciences: Mit Long-Read-Sequenzierung zum Angriff auf Illumina | ||
| CRISPR THERAPEUTICS | 44,200 | +1,38 % | Crispr Therapeutics gains amid takeover speculation | ||
| AAP IMPLANTATE | 1,370 | +1,48 % | EQS-NVR: aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: aap Implantate AG
/ Veröffentlichung der Gesamtzahl der Stimmrechte
aap Implantate AG: Veröffentlichung der Gesamtzahl der Stimmrechte nach §... ► Artikel lesen | |
| OCUGEN | 0,994 | -0,93 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,371 | -0,46 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease | RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,220 | +1,21 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| TEMPUS AI | 61,00 | 0,00 % | How Did Tempus AI Power Its Move to Positive EBITDA in Q3? | ||
| DEFENCE THERAPEUTICS | 0,502 | +3,72 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Convertible Debenture Conversion | Montreal, Quebec--(Newsfile Corp. - November 21, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation... ► Artikel lesen | |
| EDITAS MEDICINE | 2,119 | +1,05 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen |
FORTREA HOLDINGS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 8,600 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTREA HOLDINGS INC finden Sie auf Wallstreet Online.